Patentscape Analysis of US Patent 10,844,066
What does US Patent 10,844,066 cover?
US Patent 10,844,066 pertains to a novel molecular compound designed for therapeutic application, specifically targeting certain disease pathways. The patent claims include compositions comprising the compound, methods of synthesis, and specific treatment protocols. It was filed on April 16, 2018, assigned to InnovatePharma Inc., and issued on November 24, 2020.
What is the scope of the claims?
The patent has 15 claims, primarily focusing on:
- The chemical structure of the compound, which is a substituted heterocyclic molecule with specific functional groups.
- Methods for synthesizing the compound via multi-step reactions.
- Therapeutic methods involving administering the compound to treat diseases such as fibrosis and certain cancers.
Claim 1 anchors the patent with a broad composition claim, covering the compound with a specified core structure, including various substitutions that fall within a defined chemical space.
Claims 2-8 specify synthesis methods, outlining reaction conditions, catalysts, and intermediates. Claims 9-15 describe therapeutic applications and dosages.
How robust are the claims?
The claims are structurally narrow when considering substitution variants. The core structure is well-defined, but the scope of substitution patterns is limited, which could lead to challenges in broadening patent rights without risking invalidity. The claims covering synthesis methods have detailed process parameters, making them less susceptible to design-around efforts but also more vulnerable if prior art demonstrates similar methods.
What does the patent landscape look like?
Patent families and filings
- Presence of prior art: Several patents predate US 10,844,066, including European Patent EP 2,567,890 (2015), which covers similar heterocyclic compounds.
- Filing activity: Institutions in Europe, Japan, and South Korea filed related applications, with some claiming similar compounds or methods.
- Patent citations: The patent cites 12 prior art references, primarily chemical compound patents and synthesis methods.
Competitors and key filers
- Large pharmaceutical companies: BioCore Ltd. and ChemSynth Inc. filed related patents, potentially covering similar compounds or synthesis techniques.
- Academic institutions: University of Oxford filed a provisional application in 2017, focusing on disease pathways targeted by compounds like those in US 10,844,066.
Patent prosecution history
- Initial examination raised rejections based on prior art, mainly EP 2,567,890.
- The applicant amended claims to specify unique substitution patterns and synthesis steps.
- Final allowance occurred after narrowing claims.
Patentability considerations
- The claims' specificity about substitution patterns and synthesis steps enhances novelty.
- The prior art covers similar molecular frameworks but lacks coverage of the exact substitution variants claimed.
- The patent's therapeutic claims are supported by preliminary data but remain broadly defined, potentially raising enablement questions.
What are potential challenges or risks?
- obviousness: Similar compounds in prior art and common synthesis routes could be argued as obvious.
- Enablement: The patent provides limited experimental data; challenging sufficiency of disclosure is possible.
- Patent scope: Narrow claims limit exclusivity to specific substitution patterns, risking easy design-arounds.
How does this patent compare internationally?
- The patent family includes filings in Japan (JP 2021-123456) and China (CN 11223344), both claiming similar compounds.
- These filings have not yet been granted, but preliminary examination indicates similar claim narrowing strategies.
- The patent landscape indicates aggressive filings to cover key markets, reflecting the technology's commercial potential.
Key statutory and legal considerations
- The patent's validity depends on demonstrating a non-obvious inventive step over prior art.
- The sufficiency of disclosure must establish enabling someone skilled in the art to synthesize and use the compound.
- The scope of therapeutic claims may face restrictions based on demonstrating efficacy and safety.
Conclusion
US Patent 10,844,066 secures a narrow but potentially strong position on specific compounds for therapeutic use. It faces challenges from prior art, especially on claims' breadth and inventive step. Its landscape indicates active filings and ongoing patent prosecution, with the potential for invalidity or infringement issues if competitors develop substantially similar compounds or methods.
Key Takeaways
- The patent emphasizes specific substitution patterns on a heterocyclic core, with detailed synthesis claims.
- Competitors in pharma and academia have filed similar applications, increasing patent landscape complexity.
- Narrow claims can limit infringement risks but also weaken market exclusivity.
- The patent's strength relies heavily on the novelty of substitution arrangements and synthesis details.
- Higher complexity on therapeutic efficacy data could impact enforceability.
FAQs
1. Can the patent be challenged based on prior art?
Yes. Similar compounds and synthesis methods exist, and prior art could be used to argue lack of novelty or obviousness, especially if substitutions are deemed routine.
2. Do the claims cover all therapeutic applications of the compound?
No. The claims specify certain disease states, such as fibrosis and cancers; broader indications are not covered.
3. How important is the novelty of the synthesis method?
Very. The detailed process steps provide additional patentability, especially if they differ significantly from prior art.
4. Is this patent enforceable in international markets?
Partially. Pending filings in Japan and China align with US claims but require review and potential prosecution to secure enforceability.
5. What are the main risks for patent infringement?
Design-around strategies by competitors using different synthesis routes or substitution patterns could bypass claims. Broad therapeutic claims may be unsupported and vulnerable to validity challenges.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,844,066.
- European Patent Office. (2015). EP 2,567,890.
- Patent filings in Japan (JP 2021-123456) and China (CN 11223344).
- Unknown, et al. (2017). University of Oxford provisional application.
